CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Norgestrel 0.075 mgdrug
Likely dose
Norgestrel 0.075 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03585712
NCT03585712Phase 2Completed
CompareCT.gov

A Prospective, Multi-center, Randomized, Cross-over Study to Assess the Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

HRA Pharma·interventional·Posted Jul 13, 2018·Updated Jun 3, 2021

In Brief

A Phase 2 clinical trial evaluating Norgestrel 0.075 mg for Contraception. Completed, enrolled 52 participants across 2 sites.

Detailed Summary

Norgestrel 75 mcg is a progestin-only pill (POP), which is a kind of oral birth control pill. To be effective in preventing pregnancy, this kind of birth control pill is supposed to be taken every day at the same time, without delaying the intake for more than 3 hours. This study aims to find out if taking the pill 6 hours late or not taking it for one day will affect the way it works.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
CollaboratorsPremier Research

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 13, 2018
Enrollment StartJul 24, 2018
Primary CompletionApr 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.0 years ago

Interventions

Norgestrel 0.075 mgdrug

Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3